Latest Articles on Gene Therapy
Overview of latest articles and publications on gene therapy in PubMed, including Human Gene Therapy, Journal of Molecular Medicine and Journal of Gene Medicine. PubMed is a service of the US National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals.
- Impact of reactive changes on multigene testing: histopathologic analysis of low-grade breast cancers with high-risk 21-gene recurrence scores Thu, 28 Sep 2023 06:00:00 -0400
CONCLUSION: We provide further evidence that reactive stromal changes and/or low-PR scores enhance the elevation of the RS. A high-RS result in low grade, PR-positive BC may not reflect actual risk and any suspected discrepancies should be discussed with the management teams. Multigene testing results should be interpreted after correlation with pathologic findings to optimize patient care.Please confirm if the author names are presented accurately and in the correct sequence (given name, middle...
- Mincing bovine articular cartilage with commercially available shavers reduces the viability of chondrocytes compared to scalpel mincing Thu, 28 Sep 2023 06:00:00 -0400
CONCLUSION: Mincing bovine articular cartilage with commercially available shavers reduces the viability of chondrocytes compared to scalpel mincing immediately after harvest and after seven days in culture. This suggests that mincing cartilage with a shaver should be considered a matrix rather than a cell therapy.
- Multi-luminance mobility testing after gene therapy in the context of retinal functional diagnostics Thu, 28 Sep 2023 06:00:00 -0400
BACKGROUND: Voretigene neparvovec (Luxturna®) is the first approved gene therapy for RPE65-linked Leber congenital amaurosis (LCA). Though individual effects are highly variable, most recipients report improved vision in everyday life. To describe such effects, visual navigation tests are now frequently used in clinical trials. However, it is still unclear how their results should be interpreted compared to conventional parameters of visual function.
- Application of graphene oxide in tumor targeting and tumor therapy Thu, 28 Sep 2023 06:00:00 -0400
Graphene oxide (GO), as a kind of two-dimensional sp2 carbon nanomaterials, has attracted great attention in many fields in the past decade. Due to its unique physical and chemical properties, GO is showing great promise in the field of biomedicine. For GO, all the atoms on its surface are exposed to the surface with ultra-high specific surface area, and a variety of groups on the surface, such as carboxyl, hydroxyl and epoxy groups, can effectively bind/load various biomolecules. Due to the...
- Hub gene identification and molecular subtype construction for Helicobacter pylori in gastric cancer via machine learning methods and NMF algorithm Thu, 28 Sep 2023 06:00:00 -0400
Helicobacter pylori (HP) is a gram-negative and spiral-shaped bacterium colonizing the human stomach and has been recognized as the risk factor of gastritis, peptic ulcer disease, and gastric cancer (GC). Moreover, it was recently identified as a class I carcinogen, which affects the occurrence and progression of GC via inducing various oncogenic pathways. Therefore, identifying the HP-related key genes is crucial for understanding the oncogenic mechanisms and improving the outcomes of GC...
- Increased activity of inflammation-related signaling pathways in anthracycline- paclitaxel resistant breast carcinomas Thu, 28 Sep 2023 06:00:00 -0400
A frequently recommended systemic therapy for breast cancer involves a combination of anthracyclines and taxanes, however, approximately 30% of patients experience recurrence. We aimed to investigate the mechanisms of resistance to anthracycline-paclitaxel based treatment by analyzing gene expression patterns in tumor samples collected during surgery and subsequent therapeutic responses. A database of 187 patients with information about relapse-free survival (RFS) allowed the analysis of 10,017...
- he importance of mTOR hyperactivity and RICTOR amplification, and the associated targeted therapy possibilities in malignant tumours Thu, 28 Sep 2023 06:00:00 -0400
Failures of anti-tumour therapies and drug resistance initiate difficulties in cancer treatments often caused by alterations in signalling network activity, including PI3K/Akt/mTOR hyperactivity due to oncogenic mutations. In this review, we summarise the relevance of mTOR (mechanistic target of rapamycin) dysregulation identified decades ago, which is now known to be characteristic of many tumours. In this context, we present differences in activity, function and testability of mTOR kinase...
- Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy Thu, 28 Sep 2023 06:00:00 -0400
Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. Main complications include the development of arrhythmias and heart failure, and the latter may be triggered by left ventricular outflow tract obstruction. The treatment of left ventricular outflow tract obstruction includes pharmacological therapies (beta-blockers, calcium channel blockers, disopyramide) and septal reduction therapies (alcohol septal ablation, surgical myectomy). Myosin inhibitors represent a new therapeutic...
- Thromboelastographic and Gene Polymorphism Bimodality Detection for Dual Antiplatelet Aggregation Therapy in Individuals with Clopidogrelresistant Symptomatic Intracranial Artery Stenosis Thu, 28 Sep 2023 06:00:00 -0400
CONCLUSION: Using thromboelastographic and gene polymorphism bimodality detection, we found switching to ticagrelor antiplatelet aggregation therapy as better than switching to cilostazol in patients with symptomatic intracranial large artery stenosis being resistant to clopidogrel tablets. The results may be biased due to the study being a single-centre study and having a limited sample size.
- Anoikis-related gene signatures can aid prognosis of lung adenocarcinoma Thu, 28 Sep 2023 06:00:00 -0400
CONCLUSIONS: The anoikis score was associated with poor prognosis in LUAD patients. Anoikis-related genes were associated with tumor immune dysregulation and TP53 mutation in LUAD. This study opens a new perspective for LUAD therapy.
- Differential Expression of miR-21-5p, miR-20a-5p, TGF-β1, and TGF-β Receptor 2 in Skin, Serum, and Lung Samples Exposed to Sulfur Mustard Thu, 28 Sep 2023 06:00:00 -0400
Sulfur mustard (SM) or mustard gas is a blister chemical agent that causes pulmonary damage by triggering inflammation and oxidative injury. Alterations in microRNA (miR) transcript levels are found in pulmonary diseases and even inflammation. Therefore, we evaluated the expression levels of miR-20a-5p, miR-21-5p, and two target transcripts (transforming growth factor-beta [TGF-β1] and TGF-β receptor 2 [TGFR2]) in lung, serum, and skin samples from patients exposed to SM. Total RNA was extracted...
- Outcome and etiology of fetal pleural effusion, fetal ascites, and hydrops fetalis after fetal intervention: retrospective observational cohort from a single institution Thu, 28 Sep 2023 06:00:00 -0400
CONCLUSIONS: The etiologies of NIHF are heterogeneous, and the long-term (2- to 11-year span) outcomes of fetal interventions vary and are correlated with the underlying etiologies. Genome-wide tests, such as WES, are helpful for prenatal diagnosis and possibly alter the future fetal therapy strategies of NIHF. This article is protected by copyright. All rights reserved.
- HLA-C*04:09N is expressed at the cell surface and triggers peptide-specific T-cell activation Thu, 28 Sep 2023 06:00:00 -0400
The null allele HLA-C*04:09N differs from HLA-C*04:01 in a frameshift mutation within its cytoplasmic domain, resulting in translation of 32 additional amino acids that are assumed to prevent cell surface expression. However, we recently identified a multiple myeloma-reactive T-cell receptor (TCR) that appeared to recognize antigen presented on HLA-C*04:09N and encouraged us to ask whether HLA-C*04:09N, albeit not easily detectable at the cell surface, can present antigen sufficient for T-cell...
- Neurologic orphan diseases: Emerging innovations and role for genetic treatments Thu, 28 Sep 2023 06:00:00 -0400
Orphan diseases are rare diseases that affect less than 200000 individuals within the United States. Most orphan diseases are of neurologic and genetic origin. With the current advances in technology, more funding has been devoted to developing therapeutic agents for patients with these conditions. In our review, we highlight emerging options for patients with neurologic orphan diseases, specifically including diseases resulting in muscular deterioration, epilepsy, seizures, neurodegenerative...
- Personalized clinical managements through exploring circulating neural cells and electroencephalography Thu, 28 Sep 2023 06:00:00 -0400
CONCLUSION: We highlighted application of the single CNCs and correlated Ratio based between Brain channels by providing the 5xP personalized clinical management model for an early detection and therapy of the patients with AD and their targeted/predisposed relatives. Novel-evolutionary/hypothetic/heterogenic-results in brain-channels offer personalizd/constructive markers with unlimited cooperation in health and disease.
- Retrospective observational study of a novel smartphone app on the management of patients with mild cognitive impairment or mild dementia Thu, 28 Sep 2023 06:00:00 -0400
INTRODUCTION: In this study, we aimed to evaluate the feasibility, utility, and potential effects of LQ-M/D App, a smartphone application developed by Life Quest Inc., Tokyo, Japan, for patients with mild cognitive impairment (MCI) and mild dementia. The app incorporates cognitive and physical exercise training, lifestyle habit acquisition features, and a continuity improvement feature added in the post-update version to enhance user engagement. The continuity improvement feature includes the...
- Cardiac safety assessment of a novel recombinant bispecific antibody targeting the ether-à-go-go related gene 1 (hERG1)-β1 integrin macromolecular complex Thu, 28 Sep 2023 06:00:00 -0400
Introduction: In the last decades, mounting evidence has pointed out the human ether-á-go-go-related gene (hERG1) potassium channel as a novel biomarker in human cancers. However, hERG1 sustains the cardiac repolarizing current IKr and its blockade can induce a prolonged QT interval at the ECG, which increases the risk of life-threatening arrhythmias. This represents a major hindrance for targeting hERG1 for antineoplastic therapeutic purposes. Based on our discovery that hERG1 resides in a...
- Long non-coding RNAs as potential biomarkers or therapeutic targets in gastric cancer Thu, 28 Sep 2023 06:00:00 -0400
CONCLUSION: In order to promote cancer therapeutics and give knowledge on the process of carcinogenesis, our study projected a network of drug-gene interactions for discovered genes and presented relevant prospective biomarkers for the prognosis of patients with stomach cancer.
- Network analysis of liver cancer: a system biology approach Thu, 28 Sep 2023 06:00:00 -0400
CONCLUSION: Analysis revealed that AKT1, HRAS and the related biochemical pathways (especially "HIF-1 signaling pathway") are the possible diagnostic and therapeutic agents of liver cancer.
- Medical Challenges of a Common Variable Immunodeficiency With a TNFRSF13B Gene Mutation in a Simultaneous Kidney and Pancreas Transplant Recipient Thu, 28 Sep 2023 06:00:00 -0400
Common variable immune deficiency (CVID) is a primary immunodeficiency disorder, with hypogammaglobulinemia and increased susceptibility to recurrent infections, autoimmune disorders, granulomatous diseases and malignancy. Among the solid organ transplant (SOT) recipient population, those with primary immunodeficiency disorders under chronic immunosuppression therapy can theoretically be at higher risk of atypical infections, autoimmune complications and disease recurrence with suboptimal long...
Gene Therapy News
- Advancement of potential gene therapy could offer new hope for children with Batten disease - News-Medical.Net
Thu, 28 Sep 2023 18:58:0 GMT
- 'We've hit the nadir': Penn's Dr. James Wilson sees brighter days ahead for cell and gene therapy - Philadelphia Business Journal
Thu, 28 Sep 2023 17:59:0 GMT
- Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy ... - pink.citeline.com
Thu, 28 Sep 2023 16:13:1 GMT
- Cell and Gene Therapy Bioanalytical Testing Services Market 2023-2029 In-Depth Analysis and Future Foreca - Benzinga
Thu, 28 Sep 2023 15:34:4 GMT
- Cell and Gene Therapy Drug Delivery Devices Market Exclusive ... - Digital Journal
Thu, 28 Sep 2023 12:47:3 GMT